Combined oral administration of bovine collagen peptides with calcium citrate inhibits bone loss in ovariectomized rats.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
CPs | decrease | femoral bone mineral density | OVX rats | reductions in the OVX-induced decreases | showed osteoprotective effects | #1 |
CP-calcium citrate | decrease | femoral bone mineral density | OVX rats | reductions in the OVX-induced decreases | showed osteoprotective effects | #2 |
CP-calcium citrate | decrease | trabecular bone loss | OVX rats | - | prevented | #3 |
CP-calcium citrate | increase | microarchitecture of the distal femur | OVX rats | - | improved | #4 |
CP-calcium citrate | decrease | bone loss | OVX rats | - | significantly inhibited | #5 |
CP-calcium citrate | increase | bone volume | OVX rats | - | increased | #6 |
CP-calcium citrate | increase | connectivity density | OVX rats | - | increased | #7 |
CP-calcium citrate | increase | trabecular number | OVX rats | - | increased | #8 |
CP | increase | serum procollagen type I N-terminal propeptide levels | OVX rats | - | significantly increased | #9 |
CP-calcium citrate | increase | serum procollagen type I N-terminal propeptide levels | OVX rats | - | significantly increased | #10 |
CP | decrease | serum bone-specific alkaline phosphatase levels | OVX rats | - | reduced | #11 |
CP-calcium citrate | decrease | serum bone-specific alkaline phosphatase levels | OVX rats | - | reduced | #12 |
CP | decrease | serum osteocalcin levels | OVX rats | - | reduced | #13 |
CP-calcium citrate | decrease | serum osteocalcin levels | OVX rats | - | reduced | #14 |
CP | decrease | serum C-telopeptide of type I collagen levels | OVX rats | - | reduced | #15 |
CP-calcium citrate | decrease | serum C-telopeptide of type I collagen levels | OVX rats | - | reduced | #16 |
combined oral administration of bovine CPs with calcium citrate | decrease | bone loss | OVX rats | - | inhibits | #17 |
combined oral administration of bovine CPs with calcium citrate | decrease | bone loss | osteopenic postmenopausal women | - | is a promising alternative for reducing | #18 |
PURPOSE: Collagen peptides (CPs) and calcium citrate are commonly used as bone health supplements for treating osteoporosis. However, it remains unknown whether the combination of oral bovine CPs with calcium citrate is more effective than administration of either agent alone. METHODS: Forty 12-week-old Sprague-Dawley rats were randomly divided into five groups (n = 8) for once-daily intragastric administration of different treatments for 3 months at 3 months after ovariectomy (OVX) as follows: sham + vehicle; OVX + vehicle; OVX + 750 mg/kg CP; OVX + CP-calcium citrate (75 mg/kg); OVX + calcium citrate (75 mg/kg). After euthanasia, the femurs were removed and analyzed by dual energy X-ray absorptiometry and micro-computed tomography, and serum samples were analyzed for bone metabolic markers. RESULTS: OVX rats supplemented with CPs or CP-calcium citrate showed osteoprotective effects, with reductions in the OVX-induced decreases in their femoral bone mineral density. Moreover, CP-calcium citrate prevented trabecular bone loss, improved the microarchitecture of the distal femur, and significantly inhibited bone loss with increased bone volume, connectivity density, and trabecular number compared with OVX control rats. CP or CP-calcium citrate administration significantly increased serum procollagen type I N-terminal propeptide levels and reduced serum bone-specific alkaline phosphatase, osteocalcin, and C-telopeptide of type I collagen levels. CONCLUSIONS: Our data indicate that combined oral administration of bovine CPs with calcium citrate inhibits bone loss in OVX rats. The present findings suggest that combined oral administration of bovine CPs with calcium citrate is a promising alternative for reducing bone loss in osteopenic postmenopausal women.